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Abstract
Purpose To assess the clinical and cost-effectiveness of allografts versus autografts in the reconstruction of anterior cruci-
ate ligaments.
Methods Systematic review of comparative clinical effectiveness and cost-effectiveness analysis.
Results Both autograft and allograft reconstruction are highly effective. Recent studies show little difference in failure rates 
between autografts and allografts (about 6% and 7%, respectively). In cost-effectiveness analysis, the price differential is the 
main factor, making autografts the first choice. However, there will be situations, particularly in revision ACL reconstruction, 
where an allograft may be preferred, or may be the only reasonable option available.
Conclusion In ACL reconstruction, clinical results with autografts are as good as or slightly better than with allografts. 
Allografts cost more, indicating that autografts are more cost-effective and should usually be first choice.
Level of evidence II.
Introduction
Rupture of the anterior cruciate ligament (ACL) is not 
uncommon in people taking part in sports. A full descrip-
tion of the clinical aspects is provided in another article in 
this issue, by Hulet et al. [20]. ACL rupture can sometimes 
be managed conservatively but results are considered better 
with reconstruction, especially regarding stability, although 
further trials are ongoing. Non-operative approaches may 
be considered in lower demand patients but may result in 
ongoing instability, and are not cost-effective in sportspeople 
[38], whereas ACL reconstruction gives good results, and 
allows people to get back to vigorous, and indeed interna-
tional level, sport. A cost-effectiveness analysis by Stewart 
et al. [40] concluded that ACL reconstruction was cost-
effective compared to physiotherapy and no reconstruction 
in competitive athletes.
Some people do try to repair the ACL, but results do not 
so far seem to have been good. This article is only concerned 
with reconstruction.
Autografts can come from different source tendons. The 
commonest source now seems to be hamstring tendons but 
some surgeons prefer bone–patellar tendon–bone (BPTB) as 
first line, and others use BPTB in high-risk patients.
Allografts come from various sites, including tibialis 
anterior, quadriceps, Achilles tendon, BPTB and hamstrings 
(HS).
As noted by Hulet et al. [20], practice varies, with allo-
grafts used much more often in some countries than others. 
Prentice et al. [37] reported practice in six registries, in Den-
mark, Luxembourg, Norway, the UK, Sweden and the USA, 
with data from 101,125 procedures (95% from Scandinavian 
countries, 4% from the UK). In Europe, allografts were used 
in few patients (0.3–6.3%), whereas they were used in 40% 
in the US centres (Kaiser Permanente). Revision rates by 
7 years were reported for Norway (5.6%), Sweden (4.1%) 
and KP (6.1%).
The advantages of allografts are no donor site morbid-
ity, a shorter operation and less painful initial recovery. 
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The disadvantages are slower graft incorporation and 
concern about higher rupture rates in some young highly 
active groups, concern about disease transmission and 
increased cost. See review by Hulet et al. [20]. The con-
cern about a higher re-rupture rate may not be warranted 
and may date from the time when allografts were irradi-
ated or chemically cleansed, and weakened by that. Dis-
ease transmission is now rare following more rigorous 
testing of donors.
Materials and methods
Recent good-quality systematic reviews were identified 
first, followed by any recent trials not included in those 
reviews. A high-quality, recent review of both systematic 
reviews and randomised trials (RCTs) by Zeng et al. [52] 
was identified comparing allografts and autografts in pri-
mary ACL reconstruction. This review was used as the 
starting point and only primary studies that were published 
since the dates of its searches in 2014 were included. For 
completeness, eight other good-quality recent systematic 
reviews were examined. Wasserstein et al. [45], Kan et al. 
[21] and Cvetanovich et al. [12] were reviews of primary 
ACLs. A review by Mascarenhas et al. [29] was a review 
of meta-analyses. Yao et al. [50] included only studies 
before 2014 so was not discussed further. Bansal et al. [2] 
was a good-quality review but specifically on infections. It 
reported a much higher rate with HS autografts than with 
BPTB autografts, though this was based on observational 
studies, but no difference overall between autografts and 
allografts. Wei et al. [47] compared autografts with non-
irradiated allografts. Park et al. [36] also focused on the 
irradiation issue. This article does not discuss radiation 
further as it is covered in the review by Hulet et al. [20].
Two reviews by Grassi et al. [17] and Mohan et al. [30] 
considered revision ACL reconstruction. Grassi et al [17] 
found that autografts gave better results than allografts in 
revision ACL reconstruction. Whereas, Mohan et al. [30] 
found revision ACL reconstruction had failure rates similar 
to autograft or allograft reconstruction.
Cost-effectiveness analysis A decision tree model in 
Microsoft Excel® was considered the most appropriate 
choice as ACL reconstruction is usually successful and 
most patients return to a functioning knee after reconstruc-
tive surgery. The starting point for the economic model is 
the decision to do an ACL reconstruction; the model does 
not include a non-reconstruction arm. The clinical pathways 
were developed using information from the published lit-
erature and clinical experience. Further information on the 
economics model including the structure is provided in the 
full report on the ESSKA website.
Base‑case analysis
For the base-case analysis, a 3-year time horizon was 
adopted. The analysis does not differentiate by gender 
nor mortality is taken into account. The starting age for 
a patient is 25 years. The analysis is conducted from the 
perspective of the UK National Health Service (NHS) and 
personal social services (PSS). All costs are in pounds ster-
ling (£) in 2016/2017 prices. Health outcomes are meas-
ured in quality-adjusted life years (QALYs). Results are 
expressed as incremental cost-effectiveness ratio (ICER) 
more commonly known as a cost per QALY gained. An 
annual discount rate of 3.5% is applied to both costs and 
outcomes in line with recommended guidelines [31].
Resource use and costs
All unit costs reported in Table 1 are presented in pounds 
sterling (£) in 2016/17 prices. The cost of the allograft 
(£2250) was based on the NHS Tissue Services price list 
for 2018/19 [32] and was an average of the prices of the 
tendons likely to be used, such as the tibialis anterior one 
(which once doubled is the same size or thicker than the 
combined semitendinosus and gracilis graft). The exact 
prices are classed as confidential. There is no cost for the 
graft in the HS autograft arm.
It was assumed that 0.3% of all reconstructions will 
get infections based on a recent ACL study by Waterman 
et al. [46]. The cost of infections was obtained from the 
Genuario et al. paper [13] in US $ in 2010 prices. Costs 
into UK £ in 2017 prices were converted using the World 
Bank gross domestic product (GDP) deflators [48] and the 
purchasing power parity (PPP) measures [34]. The cost 
of treatment for an infection included the cost of debride-
ment, irrigation, and antibiotics started intravenously with 
1-week hospital admission then continued for a further 5 
weeks [3].
For the base-case analysis, probabilities for the decision 
model were obtained from the literature and clinical expert 
opinion (see Table 2). For the 1st ACL reconstruction, these 
probabilities were obtained from a systematic review and 
meta-analysis of randomised controlled trials which focused 
on autograft versus allograft in ACL reconstruction by Zeng 
et al. [52]. Five trials were included in the forest plot meta-
analysis for the subgroup analysis of autograft versus non-
irradiated allograft failure (Fig. 1) ([24, 33, 41–43]). There 
were 16 events in the autograft arm which resulted in a fail-
ure rate of 5.57% (n = 287) and there were 20 events in the 
allograft arm with a failure rate of 6.92% (n = 289).
For the second ACL reconstruction, probabilities 
were obtained from the paper by Mohan et al. [30], who 
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conducted a random effects meta-analysis of clinical 
outcomes in revision ACL reconstruction. The primary 
outcome was graft failure. Eight studies with a combined 
number of 2302 patients provided an autograft failure 
rate of 4.1% (95% CI 2.0–6.9%) and two studies with a 
combined number of 671 patients provided an allograft 
failure rate of 3.57% (95% CI 1.38–6.74%).
Utilities
For patients who have a successful ACL reconstruction, 
population norm values provided by Ara and Brazier [1] 
were used. Genuario et al. [13] reported utility values for 
different types of graft for ACL reconstruction. For patients 
in whom either an autograft or an allograft fails or who 
are in the conservative care arm, a utility value of 0.790 
was assigned, which corresponded to the instability health 
state. For the few patients who get an infection, a disutility 
value for 6 weeks was applied. These utility values were 
then weighted by the length of time in that health state to 
estimate QALYs.
Results
Zeng et al. [52] reviewed systematic reviews and RCTs com-
paring allografts and autografts in people having primary 
ACL reconstruction. The review of reviews included ten sys-
tematic reviews and nine RCTs. The review was assessed as 
very high quality (eight of eight quality items rated as ‘yes’). 
Autograft versus allograft (some of which used irradiated 
grafts) had a pooled risk ratio on the overall International 
Knee Documentation Committee (IKDC) level ‘normal 
and nearly normal’ of 1.03 (95% CI 1.00, 1.07); p = 0.03, in 
favour of autograft. There was no statistical heterogeneity 
Table 1  Resource use and costs for ACL reconstruction
Resource use Unit cost (£) Source
Graft type
Allograft £2250 [32]
Procedure
Intermediate knee procedures for non-trauma, 19 years and over (HRG code: HN24C) £1642 [15]
Other related costs
Three consultant led outpatient follow-up attendance (HRG code: WF01A) £336 [15]
8 hospital physiotherapy sessions (30 min) £132 [10]
Paracetamol (two tablets twice a day per year) £23.21 [5]
Ibuprofen (one tablet a day per year) £12.47 [5]
Total costs
Allograft £4395
HS autograft £2145
BPTB autograft £2145
Infection
Infections £7761 [13]
Conservative care
One consultant led outpatient follow-up attendance (HRG code: WF01A) £112 [15]
8 hospital physiotherapy sessions (30 min) £132 [11]
Table 2  Probabilities for ACL reconstruction
Pathway Probability Source
Allograft pathway
1st Allograft
 Success 0.931 [50, 52]
 Fail 0.069
2nd or 3rd Allograft
 Success 0.964 [30]
 Fail 0.036
HS autograft pathway
1st HS Autograft
 Success 0.944 [52]
 Fail 0.056
2nd or 3rd Allograft
 Success 0.964 [30]
 Fail 0.036
2nd or 3rd BPTB Autograft
 Success 0.959 [30]
 Fail 0.041
2nd or 3rd HS Autograft (other leg)
 Success 0.959 [30]
 Fail 0.041
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(I2 0%). However, when two studies were excluded in sensi-
tivity analyses (the review examined single-study influence 
on results by removing one at a time) the pooled RR was 
no longer statistically significant. Clinical failure was also 
less frequent (RR, 0.47; 95% CI 0.31, 0.73; p = 0.0007; I2 
23%), and Tegner scores (WMD, 0.36; 95% CI 0.11, 0.60; 
p = 0.004; I2 0%) differences were also statistically signifi-
cant, but the Lysholm score was not (weighted mean dif-
ference, WMD, 0.02; 95% CI − 0.71, 0.75; non-significant 
(n.s.); I2 44%). These analyses included studies using irradi-
ated allografts. Subgroup analyses of autograft versus non-
irradiated allografts were also reported for these outcomes, 
none of which were statistically significant (Lysholm WMD, 
− 0.64; 95% CI − 1.45, 0.17; n.s.; I2 0%; Tegner WMD 0.16; 
95% CI − 0.16, 0.47; n.s.; I2 0%). The authors concluded 
that autograft had advantages over irradiated allograft with 
respect to function and stability, whereas there were no sig-
nificant differences between autograft and non-irradiated 
allografts.
Mariscalco et al [28] included nine studies comparing 
autografts with non-irradiated allografts, four of which were 
RCTs or mainly RCT (one trial had 25% patient choice and 
75% randomised), with the other studies mainly patient 
choice. They found no difference in outcomes.
One review by Lording et al [25] did report a higher fail-
ure rate with non-irradiated allografts than with autografts, 
but the differences from previous reviews arose mainly from 
the inclusion of two studies, Bottoni et al. [4], and a study in 
people aged under 25 [22].
One of the primary studies, Gorschewski et  al. [14] 
reported an unusually high failure rate with BPTB allografts, 
with failures in 21% at 2 years and 45% by 6 years in the 
allograft group, compared to 5% and 6% in the autograft 
group. The allografts were treated with the Tutoplast meth-
ods and were irradiated.
Failure and revisions, allografts versus autografts
Three of the primary studies reported failures and revision 
rates for allografts and autograft ACL reconstructions. In 
the RCT by Yoo et al. [51] at 33–35 months follow-up, the 
rates of revision were similar between groups (allografts 
1.6%; autografts 1.5%). The rate of failure requiring revi-
sion was statistically significantly higher in the allograft 
group of the Bottoni et al. [4] RCT than the autograft group 
(26.5% and 8.3%, respectively, p = 0.03, duration of follow-
up 10.5 years). In the third study by Yang et al. [49], the 
failure rates at 2.5 years were 2.4% with allografts and 2.2% 
autograft. All three studies used fresh-frozen non-irradiated 
allografts.
The reasons for the higher failure rate in Bottoni et al. [4] 
are not clear. The operations were done a long time ago, per-
haps at a time when processing methods were more damag-
ing. Grafts came from a single tissue bank over a relatively 
short period of time.
Concerns has been expressed by some reviewers of a 
higher failure rate in allografts used in patients under the 
age of 25 [6]. Kane et al [22] found a higher revision rate in 
non-irradiated allograft BPTB grafts, but the potential for 
selection bias in that study was very high. In the large Kaiser 
Permanente database [26, 44], an increased rate of failure 
was noted for BPTB allografts compared to autografts which 
may explain the perceived differences. There was no statisti-
cal difference seen when autografts were compared to non-
processed soft tissue allografts in the Kaiser Permanente 
series, although follow-up remains relatively short for this 
analysis [16].
Clinical scores
The Zeng meta-analysis [52] has been updated with the addi-
tion of some more recent studies as shown in Figs. 1 and 2.
Adverse events
Hardy et al [19] provide a systematic review specifically 
on the adverse events after harvesting autografts for ACL 
reconstruction. They note that in France most ACL recon-
structions are done with autografts, taken from hamstring 
tendons, patellar tendon and fascia lata. They included 36 
Fig. 1  Updated meta-analysis of non-irradiated allografts versus autografts, Tegner score
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articles in a good-quality review. For hamstring autografts, 
they conclude that there are complications in 8.3% of cases 
(though some studies have much higher rates). The com-
monest is saphenous nerve damage, though they think this 
is largely avoidable by a different approach. Temporary 
strength deficits (up to 3 months) occur. Because these 
complications are temporary, they will have insignificant 
impact on the long-term economics.
They estimate fewer complications with patellar ten-
don (PT) grafts (0.2–1.2% overall) but some more serious, 
including patellar fracture in 0.42–1.3%, rupture of PT and 
anterior knee pain, reported in as many as 46%, but with 
varying definitions.
To guide practice, an evidence review from New Zea-
land from Accident Compensation Corporation Research 
[39] has been produced. It was based on an overview 
of 12 systematic reviews. The primary studies were not 
examined. The last search was done in May 2016, and 
the reviews were published from 2007 to 2015. The ACC 
report concluded that there was no evidence of any signifi-
cant differences in failure rates or other outcomes, between 
autografts and non-irradiated allografts. It concluded that 
allografts irradiated with low doses still performed less 
well than non-irradiated allografts, and that low doses 
were not sufficient to eliminate the risk of disease trans-
mission. Given the similar outcomes, cost became the 
determining factor. It appears that costs of allografts are 
higher in NZ than elsewhere because there is no local 
provider.
Older studies may not reflect modern processing meth-
ods. Fresh-frozen allografts give better results. Mardani-
Kivi et al. [27] found no difference in outcomes between 
fresh-frozen tibialis posterior allografts and hamstring 
autografts after 55 months. Krych et al. [23] reported a 
meta-analysis showing that BPTB autografts did better 
than allografts, but the advantage only applied when allo-
grafts were irradiated or chemically processed.
Cost‑effectiveness
Previous studies
Salzmann et al. [38] provide a review of 24 economic stud-
ies in ACL reconstruction (ACLR). They note that 17 were 
reports only of costs, of which five compared autograft and 
allograft ACLR. The other seven include three cost-utility 
studies of ACLR versus non-operative management, with 
all three concluding that surgery was more cost effective. 
Two studies compared the cost-effectiveness of single ver-
sus double-bundle techniques. One study compared prompt 
versus delayed ACLR. The remaining study by Genuario 
et al. [13] was the one most relevant to this review, because 
it compared autografts with allografts. They found that 
hamstring autograft was least costly and more effective, 
than both BPTB and allograft reconstructions.
Some studies report small differences in in-patient 
stays. Gorschewski et al. [14] reported mean stays of 5.2 
days for allografts and 6.3 days for autografts. They also 
reported a slightly earlier return to work after allografts 
(2.3 months versus 2.6 months, p = 0.004).
Cooper and Kaeding [9] report hospital costs for ACL 
reconstruction of $4,072 for autografts and $5,195 for 
allografts. The slightly shorter theatre time for allografts 
had little effect on the cost differential.
Oro et  al. [35] also report that operating time was 
12 min longer with autograft but the total cost was about 
$1000 more with allograft.
Cohen et al. [7] report that saphenous nerve damage is 
commoner after ACLR with autografts, but not enough to 
be economically significant.
Greis et al. [18] compare costs of tibialis allografts with 
hamstring autografts in Utah. The mean cost of ACLR 
allografting was $4587 with theatre time of 92 min. The 
autograft cost was $3489 with 125 min of theatre time.
Fig. 2  Updated meta-analysis of non-irradiated allografts versus autografts, Lysholm score
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Cole et al. [8] report hospital charges of $4622 for allo-
grafts and $5694 for autografts. The difference is due to 
longer operating theatre time and longer inpatient stays for 
autograft patients.
One issue to be considered in interpretation of all cost-
effectiveness studies is how old the clinical effectiveness 
data that support them are. For example, older studies may 
have a mixture of allografts sterilised by different methods, 
including radiation. The high-quality review by Zeng et al. 
[52] showed no difference in success rates when allografts 
were compared with non-irradiated grafts, but that auto-
grafts were more successful than irradiated grafts.
Modelling
Table 3 shows the base-case deterministic results.
Having an allograft as a primary ACL reconstruction 
is more costly (£2,426 more) and no more effective (very 
slightly less effective at 0.0026 QALYs—though this is 
not clinically significant) than having a HS autograft as a 
primary ACL reconstruction: that is, HS autografts “domi-
nated” allografts. The main cost driver for this result was the 
cost of the graft. The second but less important factor was 
that the failure rate for allograft was slightly higher, by 1.3% 
(6.9% versus 5.6%) than the HS autograft. However, this has 
little impact compared to allograft cost.
There are some small advantages for allografts—slightly 
shorter theatre time, no donor site morbidity—but these fac-
tors are too small to significantly affect cost-effectiveness.
Discussion
When there are existing good-quality reviews, it is unneces-
sary and indeed wasteful to repeat them. They should simply 
be updated with any new trials, as has been done in this 
article. There have been numerous reviews and RCTs in this 
area, mostly with consistent results. Where there are differ-
ences in the failure rates of ACL reconstructions between 
allografts and autografts, these can mostly be explained by 
the use of irradiated grafts. Giving sufficient radiation to 
achieve sterility will likely weaken grafts and make them 
more likely to fail and, therefore, the practice of irradiating 
grafts is not recommended.
The evidence shows no significant differences in clinical 
effectiveness between autografts and non-irradiated allo-
grafts. Failure rates with both grafts are now low. BPTB 
allografts have been described as having higher failure rates 
in some studies, compared to autograft, but this does not 
seem to be the case for soft tissue allografts, with only one 
RCT showing a difference between soft tissue allograft and 
autografts [4], whilst the majority of RCTs had failure rates 
that were very similar. The RCT by Bottoni et al [4] that 
showed a difference had an unusually high allograft failure 
rate of 27%. The reasons for this are not clear. The opera-
tions were done a long time ago, perhaps at a time when 
processing methods were more damaging. Grafts came from 
a single tissue bank over a relatively short period of time.
Failure does not necessarily mean that there was some-
thing wrong with the procedure or the technology. It should 
be borne in mind that people having these procedures do so 
because they have damaged or ruptured their own tissues, 
perhaps by putting great demands on the knee structures, 
often during sport.
When an intervention has a higher cost than the compara-
tor, but is no more clinically effective, or less effective, it is 
said to be “dominated” in cost-effectiveness analysis as is 
the case with allografts in this study. Costs with allografts 
are higher because of the cost of the graft, and the cost we 
used may be less than that in other countries. The findings of 
the economic modelling need to take into account the local 
costs of the graft, but this can be done simply based on the 
data shown here, as the cost of the graft was the dominant 
factor in the economic model.
There is less morbidity with allografts because they are 
not harvested from the live patient, but the disutility is tran-
sient and insufficient to change the overall conclusion on 
cost-effectiveness. Hardy et al [19] specifically conducted 
a review on the adverse events after harvesting autografts 
for ACL reconstruction. For hamstring autografts, they 
conclude that there are complications in 8.3% of cases, the 
commonest is saphenous nerve damage. Temporary strength 
deficits (up to 3 months) occur. Because these complications 
are temporary, they will have insignificant impact on the 
long-term economics [19].
Revision ACL reconstruction is also an effective opera-
tion, using the hamstring or BPTB graft from either the same 
leg or the other leg. This study was not directly designed 
to compare allograft and autograft usage for revision ACL 
Table 3  Base-case deterministic 
discounted results, ACL 
reconstruction
ICER incremental cost-effectiveness ratio
Procedure Total mean 
costs £
Total mean 
QALYs
Incremental costs Incremental QALYs ICER
HS autograft £2420 2.6980 – – –
Allograft £4846 2.6953 £2426 − 0.0026 Dominated
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reconstruction, but a review of the literature shows no differ-
ence in failure rate between allograft and autograft revision 
ACL reconstruction and, therefore, the cost of the allograft 
will continue to dominate the economic analysis.
There may be situations in which allografts should be 
considered. The review has assumed that a direct choice can 
be made between allografts and autografts, and that both are 
available. There may be situations where a satisfactory auto-
graft is not available, for example in multi-ligament injury 
where available autografts will be used for other reconstruc-
tions. Also, in the setting of revision ACL reconstruction, 
there are various considerations regarding graft choice, due 
to tunnel size or position, previous usage of other grafts, and 
reconstructions in the other leg, that may mean that allo-
grafts would be preferred to autografts. The other population 
not covered sufficiently in the literature for us to draw con-
clusions is the elite sprinting athlete where autograft choices 
may be influenced by the effect of graft harvesting on their 
sport. However, in the majority of cases, it may be concluded 
that allograft ACL reconstruction with non-irradiated grafts 
is as safe, but more expensive then autograft ACL recon-
struction, which is preferred as it is more cost effective.
Conclusion
There is little difference in results of ACL reconstruc-
tion with autografts or non-irradiated allografts, with any 
advantage being with autografts. The cost is higher with 
allografts. So if autografts are available, allografts are not 
cost effective.
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